CW - the reason I haven’t blocked you, is so that I can Rec the posts of others responding to you. Either where their characters & motives have been falsely attacked, or as has happened on several occasions, you have been unable to back up and contextualise posts you have made.
Cleaner - That’s completely untrue. I’ve never advised anyone to block you, or any other poster. Never have, never would.
Your 12:51 post accusing me of that, reminds me of the unwarranted attacks you made on the characters of Berm & Crumbs. Also completely unjustified and something you could not back up.
Embarrassing and yet again, random.
Absolutely Burble. I’m getting caned on a few.
Some posts / posters, make me wonder why they are invested here, in the Bio industry generally, or the Stock Market at all! Perhaps a Building Society would be better for their wellbeing.
Well I guess one question might be what has happened to the 6 month evaluation by a leading biotech company and also the deal with a cell therapy company. Unless of course there is an RNS between now and the meeting. Quite possible imo, particularly given recent quality of communication uplift.
From the 10th July Pipieline Update……..
“ Scancell has developed a novel technology platform for producing monoclonal antibodies that recognise glycans with high specificity and affinity. The platform has generated revenues and the antibodies continue to yield compelling results which have led to a new 6-month evaluation by a leading Biotech company. Additional in-house data has illustrated the potential of our antibodies as chimeric antigen receptor T cell (CART) therapies providing the data for a deal with a cell therapy company. These results along with updates on SCIB1 and Modi-1 will be presented at the AACR-CIMT meeting in Milan in September 2023.”
Definitely a hangover from the £3.5m Monmouth impairment charge imo but also fair to say I think, that a large proportion of Small Caps have dropped, or are dropping and there is a wider market malaise than the drop just being unique to SDI.
Yep and Stephen Brown now finally has his feet under the table and can begin to positively impact the future of the Company. All good.
Https://www.youtube.com/watch?v=xZbkqLuiqZI
One for Haribo
Not 100% on this and happy to be corrected but this Congress would appear different to the likes of ASCO, in as much as there is no requirement for a Poster / Abstract submission in advance.
Does it follow then, that the presentation material can / will be as last minute as possible (allowing of course for prep time) and that maybe there are some new RNS implications around that? Would fit with a Q4 update.
Thinking out loud here, so kept that in mind please!
Well then TF, that must mean you’re giving the likes of Berm, Burble & Co no more than 60 secs after the Posters are uploaded, to comment on them here lol.
Come on. It’s very clear the precise timing is small beans.
The precise timing of uploading the Posters is small beans. That will happen.
What we haven’t yet seen though and in connection with the Milan Conference, is the deal progress updates promised within the infamous 10/07 Business Pipeline Update.
“ Scancell has developed a novel technology platform for producing monoclonal antibodies that recognise glycans with high specificity and affinity. The platform has generated revenues and the antibodies continue to yield compelling results which have led to a new 6-month evaluation by a leading Biotech company. Additional in-house data has illustrated the potential of our antibodies as chimeric antigen receptor T cell (CART) therapies providing the data for a deal with a cell therapy company. These results along with updates on SCIB1 and Modi-1 will be presented at the AACR-CIMT meeting in Milan in September 2023.”
I wonder if we might see a separate RNS for those elements, this week, or next.